135 related articles for article (PubMed ID: 37274551)
1. The impact of immigration on hepatitis B burden in the United States: a modelling study.
Razavi-Shearer D; Gamkrelidze I; Pan CQ; Razavi-Shearer K; Blach S; Estes C; Mooneyhan E; Razavi H
Lancet Reg Health Am; 2023 Jun; 22():100516. PubMed ID: 37274551
[TBL] [Abstract][Full Text] [Related]
2. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Hepatitis B Collaborators
Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):796-829. PubMed ID: 35738290
[TBL] [Abstract][Full Text] [Related]
3. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.
Polaris Observatory Collaborators
Lancet Gastroenterol Hepatol; 2023 Oct; 8(10):879-907. PubMed ID: 37517414
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
Tian F; Feld JJ; Feng Z; Sander B; Wong WWL
J Hepatol; 2022 Oct; 77(4):947-956. PubMed ID: 35483535
[TBL] [Abstract][Full Text] [Related]
5. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
Polaris Observatory HCV Collaborators
Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
[TBL] [Abstract][Full Text] [Related]
6. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.
Polaris Observatory Collaborators
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):383-403. PubMed ID: 29599078
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
8. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
9. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.
Alberts CJ; Clifford GM; Georges D; Negro F; Lesi OA; Hutin YJ; de Martel C
Lancet Gastroenterol Hepatol; 2022 Aug; 7(8):724-735. PubMed ID: 35576953
[TBL] [Abstract][Full Text] [Related]
10. Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study.
Tanaka J; Kurisu A; Ohara M; Ouoba S; Ohisa M; Sugiyama A; Wang ML; Hiebert L; Kanto T; Akita T
Lancet Reg Health West Pac; 2022 May; 22():100428. PubMed ID: 35637862
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus infection in immigrant populations.
Coppola N; Alessio L; Pisaturo M; Macera M; Sagnelli C; Zampino R; Sagnelli E
World J Hepatol; 2015 Dec; 7(30):2955-61. PubMed ID: 26730274
[TBL] [Abstract][Full Text] [Related]
12. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.
Degenhardt L; Charlson F; Stanaway J; Larney S; Alexander LT; Hickman M; Cowie B; Hall WD; Strang J; Whiteford H; Vos T
Lancet Infect Dis; 2016 Dec; 16(12):1385-1398. PubMed ID: 27665254
[TBL] [Abstract][Full Text] [Related]
13. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
Sanai FM; Alghamdi M; Dugan E; Alalwan A; Al-Hamoudi W; Abaalkhail F; AlMasri N; Razavi-Shearer D; Razavi H; Schmelzer J; Alfaleh FZ
J Infect Public Health; 2020 Nov; 13(11):1715-1723. PubMed ID: 32988769
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Chronic Hepatitis B Virus Infection in the United States.
Lim JK; Nguyen MH; Kim WR; Gish R; Perumalswami P; Jacobson IM
Am J Gastroenterol; 2020 Sep; 115(9):1429-1438. PubMed ID: 32483003
[TBL] [Abstract][Full Text] [Related]
15. Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
Veracruz N; Gish RG; Cheung R; Chitnis AS; Wong RJ
J Viral Hepat; 2022 May; 29(5):352-365. PubMed ID: 35274406
[TBL] [Abstract][Full Text] [Related]
16. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
17. Impact of the national hepatitis B immunization program in China: a modeling study.
Liu Z; Li M; Hutton DW; Wagner AL; Yao Y; Zhu W; Cao L; Tang S; Pan J; Wang Y; Zhao Q; Ren H; Wang Y; Wang W
Infect Dis Poverty; 2022 Oct; 11(1):106. PubMed ID: 36221140
[TBL] [Abstract][Full Text] [Related]
18. Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.
Li R; Shen M; Ong JJ; Cui F; Hu W; Chan P; Zou Z; Su S; Liu H; Zhang L; Seto WK; Wong WCW
JHEP Rep; 2023 Oct; 5(10):100833. PubMed ID: 37675271
[TBL] [Abstract][Full Text] [Related]
19. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
[TBL] [Abstract][Full Text] [Related]
20. Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia.
Taye BW; Valery PC; Clark PJ
J Viral Hepat; 2022 Oct; 29(10):868-878. PubMed ID: 35748684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
